Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance
The company reported a second-quarter 2025 adjusted earnings of 32 cents, down from 56 cents a year ago. Analysts estimated a loss of 79 cents.
The company reported quarterly sales of $773.69 million, up 17% year over year, beating the consensus of $638.55 million.Alnylam Pharmaceuticals achieved global net product revenues for Amvuttra and Onpattro for the second quarter of $492 million and $53 million.
The company achieved global net product revenues for Givlaari and Oxlumo for the second quarter of $81 million and $47 million.
Alnylam raised its fiscal 2025 sales guidance from $2.7 billion-$3 billion to $3.3 billion-$3.55 billion compared to the consensus of $2.89 billion.
Chardan Research and William Blair have both issued positive outlooks on Alnylam following the second-quarter results. Chardan Research stated that the launch of Amvuttra for ATTR-CM (Transthyretin Amyloid Cardiomyopathy) is off to an exceptionally strong start.
ATTR-CM, or transthyretin amyloid cardiomyopathy, is a rare and often underdiagnosed form of heart failure.
The company achieved approximately 1,400 ATTR-CM Patients on Amvuttra (vutrisiran) as of June 30, 2025, resulting in an approximately $150 million step-up in revenue.
View more earnings on ALNY
In March, the U.S. Food and Drug Administration on Thursday approved Amvuttra (vutrisiran) in adults with cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, or ATTR-CM.
Chardan analyst Keay Nakae on Thursday wrote, 'We believe this speaks volumes about management confidence in the near-term launch progression. Commercially we believe that the totality of the data leaves Amvuttra well positioned to achieve significant market share as 1st line therapy.'
Chardan reiterated the Buy rating, while raising the price forecast from $325 to $400.
William Blair on Thursday wrote, 'We believe that Alnylam is the premier siRNA therapeutics company, and with the P5x25 corporate strategy intact, the company is on track to achieve profitability by the end of 2025 and become a fully sustainable biotech growth story.'
Various analysts have reacted positively to Alnylam's performance, with several firms reiterating or maintaining their Buy or Overweight ratings and significantly raising their price forecasts.
Morgan Stanley maintained an Equal-Weight rating, increasing its price forecast from $312 to $405. Piper Sandler and Barclays both maintained Overweight ratings, with Piper Sandler raising its forecast from $304 to $449, and Barclays increasing its target from $329 to $460.
Raymond James reiterated an Outperform rating, boosting its price forecast from $370 to $424. Wells Fargo maintained an Equal-Weight rating, raising its price forecast from $333 to $395.
Canaccord Genuity held a Buy rating, raising its forecast from $390 to $415, while UBS also maintained a Buy rating, notably increasing its price forecast from $403 to $550.
Price Action: ALNY stock is trading higher by 1.56% to $398.36 at last check Friday.
Read Next:Photo via Shutterstock
Latest Ratings for ALNY
Date
Firm
Action
From
To
Mar 2022
Citigroup
Initiates Coverage On
Buy
Feb 2022
Morgan Stanley
Maintains
Overweight
Feb 2022
SVB Leerink
Maintains
Market Perform
View More Analyst Ratings for ALNY
View the Latest Analyst Ratings
Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.
Get the latest stock analysis from Benzinga?
ALNYLAM PHARMACEUTICALS (ALNY): Free Stock Analysis Report
This article Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
5 Unstoppable "Ten Titans" Growth Stocks to Buy Now and Hold Through at Least 2030
Key Points The "Ten Titans" offer a more comprehensive list of top growth stocks than the "Magnificent Seven." Nvidia and Broadcom provide the building blocks of AI infrastructure. Microsoft, Alphabet, and Oracle are three exciting plays in cloud computing. 10 stocks we like better than Nvidia › The "Ten Titans" are the largest growth-focused U.S. companies by market cap -- consisting of Nvidia (NASDAQ: NVDA), Microsoft (NASDAQ: MSFT), Apple, Amazon, Alphabet (NASDAQ: GOOGL) (NASDAQ: GOOG), Meta Platforms, Broadcom (NASDAQ: AVGO), Tesla, Oracle (NYSE: ORCL), and Netflix. Combined, they make up over 37% of the S&P 500, showcasing the top-heavy nature of the index and how just a handful of companies can move the market. If I could only buy and hold half of the Ten Titans through 2030, I'd go with Nvidia, Broadcom, Microsoft, Oracle, and Alphabet. Here's what separates these growth stocks from the rest of the pack. The building blocks of AI Nvidia and Broadcom both play crucial roles in the buildout of artificial intelligence (AI). Nvidia's graphics processing units, CUDA software platform, and associated infrastructure provide a full-scale AI ecosystem for data centers. Orders continue to pour in for Nvidia's chips as big tech companies ramp up capital expenditures to support AI models. Broadcom makes application-specific integrated circuits, which are AI accelerators that can perform specific functions. The company's latest customer accelerator (XPU) is its 3.5D eXtreme Dimension System in Package, which drastically cuts down on power consumption and boosts efficiency between components -- all within a smaller package size. Broadcom offers compute, memory, network, and packaging capabilities, giving customers a vertically integrated solution for AI at scale. Broadcom has a highly differentiated networking and infrastructure software business. In addition to AI accelerators, its semiconductor segment also offers a variety of solutions for enterprise clients, like broadband, wireless, storage, and more. Three different ways to bet on cloud computing Microsoft, Alphabet, and Oracle offer three distinctly different ways to invest in cloud computing. Microsoft Azure is the No. 2 cloud player behind Amazon Web Services. Azure is Microsoft's fastest-growing segment -- capitalizing on AI demand through cloud offerings specifically geared toward handling AI workloads. But what separates Microsoft from other cloud plays is the strength of the rest of its business. Copilot for Azure, the Microsoft 365 software suite, and GitHub continue to grow their active user base. Microsoft's revenue growth has accelerated, and profit margins are at their highest level in over a decade -- driving Microsoft's surging stock price. Alphabet's Google Cloud doesn't have as much market share as Azure, but it is growing quickly and becoming more profitable. But unlike Microsoft, where cloud is the centerpiece of the investment thesis, Google Cloud doesn't contribute nearly as much to Alphabet's bottom line as other services -- namely Google Search and YouTube. Alphabet stock has roared higher in recent months, but it's still arguably the best value of the Ten Titans. While Google Search could see disruption from rival information resources like ChatGPT, it's worth noting that Google Gemini has gained significant traction in recent quarters -- showing Alphabet's ability to adapt. Oracle Cloud Infrastructure (OCI) is arguably the most exciting play in cloud computing right now. OCI is thriving due to its flexible structure, which leans on Oracle's established database ecosystem. It is best paired with Oracle databases and applications, with certain services not available on other clouds. Instead of going toe-to-toe with the "big three" cloud providers, Oracle partners with them by combining its database services with the AWS, Azure, and Google Cloud infrastructure. All told, Oracle is a top play in cloud computing because it offers its own vertically integrated suite of solutions, but also stands to benefit from the overall growth of the industry through its partnerships. These titans are worth their premium price tags Nvidia, Broadcom, Microsoft, Alphabet, and Oracle have all been phenomenal stocks -- crushing the S&P 500 over the last five years. With the exception of Alphabet, outsized gains have made valuations expensive based on their trailing and forward earnings estimates, which may deter some investors from approaching these names. However, folks who are looking for top companies to buy and hold through at least 2030 will care more about where a company will be years from now than the next few quarters. The advantage of a longer investment time horizon is that you can give a company time to grow into its valuation. Nvidia, Broadcom, and Oracle are some of the most expensive of the Ten Titans, but they also have the most attractive runways for growth. Meanwhile, Microsoft and Alphabet have more reasonable valuations and multiple levers to pull for growing earnings for years to come. There are valid cases for buying all of the Ten Titans, but Nvidia, Broadcom, Microsoft, Alphabet, and Oracle truly stand out as the best of the best for long-term investors. Do the experts think Nvidia is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Nvidia make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,071% vs. just 185% for the S&P — that is beating the market by 886.18%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $663,630!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,695!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Daniel Foelber has positions in Nvidia. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Netflix, Nvidia, Oracle, and Tesla. The Motley Fool recommends Broadcom and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. 5 Unstoppable "Ten Titans" Growth Stocks to Buy Now and Hold Through at Least 2030 was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 minutes ago
- Yahoo
Fed's Daly: Two rate cuts, more or less, appropriate this year
(Reuters) -San Francisco Federal Reserve Bank President Mary Daly, in an interview following economic reports showing stronger-than-expected retail sales and an unexpected jump in wholesale prices last month, signaled that she is still on board for beginning to ease policy as soon as next month. A softening labor market, an economy that's slowing but not slow, as weighed against inflation that is still above the Fed's goal "would warrant a couple of cuts sometime this year," Daly told Fox Business' Maria Bartiromo in the interview, which aired late on Friday. "Of course, we will wait to see the data and maybe it'll be fewer, maybe it'll be more, but ultimately, I think two remains a good projection. "What I don't want to do is be so worried that inflation might come up again or be persistent that we wait for that clarity and don't support the labor market," she said. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 minutes ago
- Yahoo
Pony AI (PONY) on Track to Deliver 1,000 Gen-7 Robotaxis by Year-End
Pony AI Inc. (NASDAQ:PONY) is one of the. On August 12, the company announced its unaudited financial results for the second quarter ended June 30, 2025. It announced producing over 200 Gen-7 robotaxi vehicles as of August 11, which positions it well on track to reach its target of 1,000 vehicles by year-end. The company's second-quarter revenues increased 76% year-over-year to $21.5 million, attributed largely to its robotaxi services and licensing revenues. Robotaxi services revenues grew 158% to $1.5 million, whereas fare-charging revenues increased over 300%. A driver standing in front of an electric car, demonstrating the company's electric vehicle leasing capabilities. PONY AI reports beginning mass production of its Gen-7 robotaxi models in June and July via partnerships with Guangzhou Automobile Group and Beijing Automotive Industry Corporation. Its fully-driverless commercial robotaxi services are operated across China's four tier-one cities; whereas it has also expanded operations to Dubai, South Korea, and Luxembourg. 'This quarter marked a significant milestone in our journey toward large-scale production and deployment, further solidifying our leadership in the Robotaxi industry. Since mass production started two months ago, over 2001 Gen-7 Robotaxi vehicles have rolled off the production line, putting us firmly on track to hit the year-end 1,000-vehicle target. Our robust Robotaxi revenues more than doubled, with fare-charging revenues surging by over 300% year-over-year. The path toward positive unit economics is also clear, as we made substantial improvements in key cost items such as remote assistance and vehicle insurance. These achievements are underpinned by our rapid scaling and operational breakthroughs in all four tier-one cities in China, coupled with expanded presence in Dubai, South Korea and Luxembourg. As we enter the second half of this pivotal year of mass production, we are driving strongly toward positive unit economics and accelerating our multi-year growth trajectory.' – Dr. James Peng, Chairman and Chief Executive Officer of Pony AI Inc. (NASDAQ:PONY) specializes in autonomous mobility, offering AI-driven robotruck and robotaxi services, intelligent driving software, and vehicle integration solutions. While we acknowledge the potential of PONY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.
